As the year winds down, STAT reporters are taking a look at the stories they’re most eager to track in 2018. Find all our “three to watch” series here

The pharmaceutical industry may be flush with cash and generating some genuine breakthrough treatments, but drug makers will remain embattled in the coming year.

Pharma’s perpetual race for profits and reliance on the U.S. as its biggest customer are certain to cause tensions as Americans struggle with pocketbook anxiety over high drug prices. Similarly, various moves to fend off competition will continue to generate scrutiny. And you can be certain industry hiring and investment will be closely tracked now that drug makers are getting a windfall from the new tax bill.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy